Hormone Therapy Review for Perimenopausal Symptoms: Focused on Perimenopausal Women without Other Risk Factors.
10.24304/kjcp.2017.27.4.199
- Author:
Young Mee LEE
1
;
Hwi Yeol YUN
Author Information
1. College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea. hyyun@cnu.ac.kr
- Publication Type:Review
- Keywords:
Estrogen;
progestogen;
MHT;
perimenopause;
menopause
- From:Korean Journal of Clinical Pharmacy
2017;27(4):199-206
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
As the population ages, the life of women after menopause becomes much longer than the past, and the quality of life of old age becomes increasingly principal issue. There is a period that women experience the physical symptoms of menopause, although there are differences in degree, and the management of this period is a suitable time for women to improve their quality of life. According to the menopausal hormone therapy (MHT) and Timing Hypothesis, which has been proven in the Kronos Early Estrogen Prevention Study (KEEPS) and the Early vs Late Intervention Trial with Estradiol (ELITE) study, a relatively young woman before and after menopause can benefit from long-term beneficial effects such as prevention of osteoporosis and cardiovascular disease by early initiation of hormone therapy to alleviate menopausal symptoms. MHT should be considered for all women in healthy (without other important diseases) menopausal years, expecting to improve their quality of life through symptom relief in menopausal women and, in the long term, to prevent cardiovascular disease and osteoporosis. When applying hormone therapy to individuals, it is necessary to establish various treatment strategies according to the menopausal symptoms of individual patients (individualization of treatment) and judge the suitability of clinical application.
